Biomarkers in Ulcerative Colitis
Publication Date: February 21, 2023
Key Points
Key Points
- There is an important need for understanding how noninvasive biomarkers may serve as accurate and reliable surrogates for endoscopic assessment of inflammation.
- Commonly available biomarkers are well-established as surrogate tests for endoscopic assessment of disease and in longitudinal monitoring of patients with an established diagnosis of ulcerative colitis (UC).
- This guideline focuses on the following biomarkers: serum C-reactive protein (CRP), fecal calprotectin, and fecal lactoferrin.
Diagnosis
...Diagnosis...
...S...
...Patients With Ul...
...patients with UC in symptomatic remissi...
...cal calprotectin...
...al fecal lactoferrin (C, L)620...
...CRP (C, VL)Implementation consideration: N...
In patients with UC in symptomatic...
...Patients With Sympto...
...symptomatically active UC, the AGA suggests an e...
...l calprotectin >150 μg/g...
...ted fecal lactoferrin (C,...
elevated CRP (C, M)...
...th UC with mild symptoms, with elevated stoo...
...patients with UC with mild symptoms, with nor...
...Treat-to...
...ts with UC, the AGA makes no recom...
...mmary of Key Considerations When Using Biomark...
Treatment
...Treatment...
...nces of Diagnostic Test Results on Patient-Imp...